<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03891953</url>
  </required_header>
  <id_info>
    <org_study_id>CDKY709A12101C</org_study_id>
    <nct_id>NCT03891953</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.</brief_title>
  <official_title>A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/Ib, open label study. The escalation portion will characterize the safety&#xD;
      and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or&#xD;
      melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the&#xD;
      determination of the MTD/RD for a particular treatment arm, dose expansion will further&#xD;
      assess safety, tolerability, PK/PD, and anti-tumor activity of each regimen at the MTD/RD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">April 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 14, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of DKY709 single agent treatment or DKY709 in combination with PDR001.</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of AEs and SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>1 Month</time_frame>
    <description>The incidence of DLTs during the first cycle of treatment with single agent DKY709 or the combination of DKY709 with PDR001.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of DKY709 single agent treatment or DKY709 in combination with PDR001.</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of AEs and SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of DKY709 and PDR001</measure>
    <time_frame>24 months</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of DKY709 and PDR001</measure>
    <time_frame>24 months</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of DKY709 and PDR001</measure>
    <time_frame>24 months</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of DKY709 and PDR001</measure>
    <time_frame>24 months</time_frame>
    <description>Half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration vs time profile of DKY709 and PDR001</measure>
    <time_frame>24 months</time_frame>
    <description>Concentration vs. time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine PFS in each part of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine BOR in each part of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine DOR in each part of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine TTP in each part of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Melanoma</condition>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Microsatellite Stable Colorectal Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>DKY709</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DKY709 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DKY709 + PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with DKY709 and PDR001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DKY709</intervention_name>
    <description>Novel immunomodulatory agent</description>
    <arm_group_label>DKY709</arm_group_label>
    <arm_group_label>DKY709 + PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2</description>
    <arm_group_label>DKY709 + PDR001</arm_group_label>
    <other_name>Spartalizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent must be obtained prior to participation in the study.&#xD;
&#xD;
          2. Patients must be ≥18 years of age at the time of informed consent form (ICF)&#xD;
             signature.&#xD;
&#xD;
          3. Patients with advanced/metastatic cancer who have progressed despite having received&#xD;
             standard therapy in the metastatic setting or are intolerant to standard therapy, and&#xD;
             for whom no effective standard therapy is available&#xD;
&#xD;
          4. In expansion: patient with measurable disease as determined by RECIST version 1.1,&#xD;
&#xD;
          5. Dose escalation, patients must fit into one of the following groups:&#xD;
&#xD;
               -  NSCLC, previously treated with an anti-PD-1/PD-L1 therapy&#xD;
&#xD;
               -  Melanoma, previously treated with an anti-PD-1/PD-L1 therapy&#xD;
&#xD;
               -  NPC&#xD;
&#xD;
             Dose expansion part, patients must fit into one of the following groups:&#xD;
&#xD;
               -  NSCLC, primarily refractory to anti-PD-1/PD-L1 therapy with documented PD-L1 ≥ 1%&#xD;
&#xD;
               -  Melanoma, primarily refractory to anti-PD-1/PD-L1 therapy&#xD;
&#xD;
               -  NPC, naive to anti-PD-1/PD-L1 therapy&#xD;
&#xD;
               -  mssCRC, naive to anti-PD-1/PD-L1 therapy&#xD;
&#xD;
               -  TNBC, naive to anti-PD-1/PD-L1 therapy Primarily refractory is defined as&#xD;
                  duration of therapy with a regimen which includes an anti-PD-1/PD-L1 agent ≤ 6&#xD;
                  months prior to disease progression and no objective evidence of significant&#xD;
                  radiologic response during treatment.&#xD;
&#xD;
          6. ECOG Performance Status ≤ 2&#xD;
&#xD;
          7. Patients must have a site of disease amenable to core needle biopsy, and be a&#xD;
             candidate for tumor biopsy according to the treating institution's guidelines.&#xD;
             Patients must be willing to undergo a new tumor biopsy at baseline, and during therapy&#xD;
             on the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases&#xD;
             that require local CNS-directed therapy (such as radiotherapy or surgery), or&#xD;
             increasing doses of corticosteroids within 2 weeks prior to study entry. Patients with&#xD;
             treated brain metastases should be neurologically stable for at least 4 weeks prior to&#xD;
             study entry and off steroids for at least 2 weeks before administration of any study&#xD;
             treatment.&#xD;
&#xD;
          2. History of severe hypersensitivity reactions to any ingredient of study drug(s) or&#xD;
             other mAbs and/or their excipients.&#xD;
&#xD;
          3. Patient with out of range laboratory values defined as:&#xD;
&#xD;
               -  Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) &lt; 40&#xD;
                  mL/min&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 x ULN, except for patients with Gilbert's syndrome who are&#xD;
                  excluded if total bilirubin &gt; 3.0 x ULN or direct bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt; 3 x ULN, except for patients that have tumor&#xD;
                  involvement of the liver, who are excluded if ALT &gt; 5 x ULN&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) &gt; 3 x ULN, except for patients that have tumor&#xD;
                  involvement of the liver, who are excluded if AST &gt; 5 x ULN&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1.0 x 109/L&#xD;
&#xD;
               -  Platelet count &lt; 75 x 109/L (growth factor or transfusion support may not be used&#xD;
                  to meet entry criterion)&#xD;
&#xD;
               -  Hemoglobin (Hgb) &lt; 8 g/dL (growth factor or transfusion support may not be used&#xD;
                  to meet entry criterion)&#xD;
&#xD;
               -  Potassium, magnesium, calcium or phosphate abnormality CTCAE &gt; grade 1&#xD;
&#xD;
          4. Clinically significant cardiac disease or impaired cardiac function, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Clinically significant and/or uncontrolled heart disease such as congestive heart&#xD;
                  failure requiring treatment (NYHA grade ≥ 2), uncontrolled hypertension or&#xD;
                  clinically significant arrhythmia&#xD;
&#xD;
               -  On screening: QTcF &gt; 450 msec (male), or &gt; 460 msec (female)&#xD;
&#xD;
               -  QTc not assessable&#xD;
&#xD;
               -  Congenital long QT syndrome&#xD;
&#xD;
               -  History of familial long QT syndrome or known family history of as Torsades de&#xD;
                  Pointes&#xD;
&#xD;
               -  Acute myocardial infarction or unstable angina pectoris &lt; 3 months prior to study&#xD;
                  entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital Massachusetts Gen Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Cournoyer</last_name>
      <email>MCOURNOYER@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Justin Gainor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Israel Adam</last_name>
      <phone>617-632-3902</phone>
      <email>IsraelJ_Adam@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Awad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Drug Ship - 3</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Robinson</last_name>
      <phone>615-329-7294</phone>
      <email>Ryan.Robinson4@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Howard A Burris III</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104 0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer, melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer, Triple Negative Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

